Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

@article{McMillin2009AntimyelomaAO,
  title={Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.},
  author={Douglas W. McMillin and Melissa G Ooi and Jake Delmore and Joseph M. Negri and Patrick J. Hayden and Nicolas Mitsiades and Jana Jakubikova and Sandeep Maira and Carlos Garc{\'i}a-Echeverr{\'i}a and Robert L. Schlossman and Nikhil C. Munshi and Paul G Richardson and Kenneth C. Anderson and Constantine Mitsiades},
  journal={Cancer research},
  year={2009},
  volume={69 14},
  pages={5835-42}
}
The phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway mediates proliferation, survival, and drug resistance in multiple myeloma (MM) cells. Here, we tested the anti-MM activity of NVP-BEZ235 (BEZ235), which inhibits PI3K/Akt/mTOR signaling at the levels of PI3K and mTOR. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide colorimetric survival assays showed that MM cell lines exhibited dose- and time-dependent decreased viability after exposure to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 58 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Compartmentspecific bioluminescence imaging (CS-BLI): a highthroughput approach to identify novel anti-myeloma therapies that overcome the protection of stromal cells

  • D McMillin, J Negri, P Hayden
  • Haematologica
  • 2007
2 Excerpts

Similar Papers

Loading similar papers…